Key result
Chemotherapeutic agents, particularly anthracyclines and trastuzumab, are leading causes of cardiotoxicity manifesting as heart failure and left ventricular systolic dysfunction.
Population
Patients receiving chemotherapeutic agents, particularly anthracyclines and trastuzumab
Design
Review
Authors
Loading...
Supports vigilance for cardiotoxicity during anthracycline or trastuzumab therapy; leaves open optimal prevention and monitoring protocols.
This review summarizes current opinions and guidelines on the management of chemotherapy-induced cardiotoxicity, focusing on anthracyclines and trastuzumab.
Piper et al. (2015) conducted a review in Cardiotoxicity and Heart Failure. Chemotherapeutic agents (anthracyclines and trastuzumab) was evaluated. Chemotherapeutic agents, particularly anthracyclines and trastuzumab, are leading causes of cardiotoxicity manifesting as heart failure and left ventricular systolic dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: